Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | INSR | P06213 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19879702 | 0.87 | ADRA2A (0.56) | NPC1RAB9AL3MBTL1POLBMAPT | |
| SCHEMBL15981868 | 0.82 | MAPT (0.53) | NPC1RAB9AL3MBTL1POLBMAPT | |
| SCHEMBL15981857 | 0.82 | MAPT (0.53) | NPC1RAB9AL3MBTL1POLBMAPT | |
| SCHEMBL17854036 | 0.80 | KDR (0.43) | NPC1RAB9AL3MBTL1CYP3A4EGFR | |
| SCHEMBL15014114 | 0.80 | KMT2A (0.47) | NPC1RAB9AL3MBTL1CYP3A4POLB | |
| SCHEMBL5305710 | 0.80 | HPGD (0.45) | NPC1RAB9ACYP3A4EGFRPDGFRB | |
| SCHEMBL12017943 | 0.79 | NPC1 (0.60) | NPC1RAB9AL3MBTL1MAPTHPGD | |
| SCHEMBL16340275 | 0.79 | HPGD (0.54) | NPC1RAB9AL3MBTL1CYP3A4EGFR | |
| SCHEMBL16340696 | 0.79 | EGFR (0.51) | NPC1RAB9AL3MBTL1CYP3A4EGFR | |
| SCHEMBL16543308 | 0.79 | EGFR (0.51) | NPC1RAB9AL3MBTL1CYP3A4POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117015712-A | GPCR screening method for identifying non-magic compound | 加利福尼亚大学董事会 | 2023-11-07 | — | — | CN | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| EP-3998270-A1 | ALKYNE DERIVATIVE, PREPARATION METHOD FOR SAME, AND USES THEREOF | Zhejiang Hisun Pharmaceutical Co., Ltd. (CN) | 2022-05-18 | — | — | EP | disclosed |
| EP-3459952-B1 | PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME AND USE THEREOF IN MEDICINE | ZHEJIANG HISUN PHARM CO LTD (CN) | 2022-01-05 | — | — | EP | disclosed |
| EP-3378861-B1 | ACRYLIC ACID DERIVATIVE, PREPARATION METHOD AND USE IN MEDICINE THEREOF | ZHEJIANG HISUN PHARM CO LTD (CN) | 2021-08-04 | — | — | EP | disclosed |
| WO-2020228436-A1 | AROMATIC RING OR HETEROAROMATIC RING DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江海正药业股份有限公司 | 2020-11-19 | — | — | WO | disclosed |
| WO-2020041562-A1 | SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF-BETA AND METHODS OF TREATMENT | CLAVIUS PHARMACEUTICALS, LLC (US) | 2020-02-27 | — | — | WO | disclosed |
| US-9777012-B2 | Substituted furo[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2017-10-03 | — | — | US | disclosed |
| EP-2809157-B1 | FUNGICIDAL PYRAZOLE MIXTURES | DU PONT (US) | 2017-09-06 | — | — | EP | disclosed |
| EP-1608377-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF FAB I AND FURTHER ANTIBIOTICS | Affinium Pharmaceuticals, Inc. (CA) | 2005-12-28 | — | — | EP | disclosed |
| EP-1575951-A1 | HETEROCYCLIC COMPOUNDS, METHODS OF MAKING THEM AND THEIR USE IN THERAPY | Affinium Pharmaceuticals, Inc. (CA) | 2005-09-21 | — | — | EP | disclosed |
| US-20050043370-A1 | HIV integrase inhibitors | WALKER MICHAEL A (US) | 2005-02-24 | — | — | US | disclosed |
| US-6803378-B2 | FOR THERAPY AND PROPHYLAXIS OF ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS), OR ARC | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-12 | — | — | US | disclosed |
| WO-2004082586-A2 | PHAMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF FAB I AND FURTHER ANTIBIOTICS | AFFINIUM PHARMACEUTICALS, INC. (US) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004052890-A1 | HETEROCYCLIC COMPOUNDS, METHODS OF MAKING THEM AND THEIR USE IN THERAPY | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2004-06-24 | — | — | WO | disclosed |
| US-20030181490-A1 | HIV integrase inhibitors | WALKER MICHAEL A (US) | 2003-09-25 | — | — | US | disclosed |
| US-20030027847-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-06 | — | — | US | disclosed |
| US-4058607-A | DIHALOVINYL DIALKYL PHOSPHATE, 1,3-BENZODIOXOLES | AIRWICK INDUSTRIES, INC. (US) | 1977-11-15 | — | — | US | disclosed |
| US-3962415-A | Insecticide evaporator comprising DDVP with synergized benzodioxole compound as stabilizer | AIRWICK INDUSTRIES, INC. (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043370-A1 | HIV integrase inhibitors | AKR1C3, CBR3, CBR1 | NPC1 200/4885RAB9A 3489/4885L3MBTL1 826/4885 |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | IKZF1, IKZF3, IKZF2 | NPC1 1565/4885RAB9A 4579/4885L3MBTL1 536/4885 |
| US-20030181490-A1 | HIV integrase inhibitors | CBR1, CCR5, CCR1 | NPC1 115/4885RAB9A 3358/4885L3MBTL1 649/4885 |
| US-20030027847-A1 | HIV integrase inhibitors | CBR1, CCR5, CCR1 | NPC1 115/4885RAB9A 3358/4885L3MBTL1 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.